RU2017106896A3 - - Google Patents

Download PDF

Info

Publication number
RU2017106896A3
RU2017106896A3 RU2017106896A RU2017106896A RU2017106896A3 RU 2017106896 A3 RU2017106896 A3 RU 2017106896A3 RU 2017106896 A RU2017106896 A RU 2017106896A RU 2017106896 A RU2017106896 A RU 2017106896A RU 2017106896 A3 RU2017106896 A3 RU 2017106896A3
Authority
RU
Russia
Application number
RU2017106896A
Other languages
Russian (ru)
Other versions
RU2697851C2 (ru
RU2017106896A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2017106896A publication Critical patent/RU2017106896A/ru
Publication of RU2017106896A3 publication Critical patent/RU2017106896A3/ru
Application granted granted Critical
Publication of RU2697851C2 publication Critical patent/RU2697851C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
RU2017106896A 2014-08-13 2015-08-13 Антиметаногенные композиции и их применение RU2697851C2 (ru)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201462036948P 2014-08-13 2014-08-13
US62/036,948 2014-08-13
US201462043649P 2014-08-29 2014-08-29
US201462043789P 2014-08-29 2014-08-29
US62/043,649 2014-08-29
US62/043,789 2014-08-29
US201562141355P 2015-04-01 2015-04-01
US62/141,355 2015-04-01
PCT/US2015/045140 WO2016025762A1 (en) 2014-08-13 2015-08-13 Anti-methanogenic compositions and uses thereof

Publications (3)

Publication Number Publication Date
RU2017106896A RU2017106896A (ru) 2018-09-13
RU2017106896A3 true RU2017106896A3 (cg-RX-API-DMAC7.html) 2019-03-19
RU2697851C2 RU2697851C2 (ru) 2019-08-21

Family

ID=55301332

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017106896A RU2697851C2 (ru) 2014-08-13 2015-08-13 Антиметаногенные композиции и их применение

Country Status (12)

Country Link
US (5) US9956292B2 (cg-RX-API-DMAC7.html)
EP (1) EP3179983A4 (cg-RX-API-DMAC7.html)
JP (1) JP6667526B2 (cg-RX-API-DMAC7.html)
KR (1) KR102425303B1 (cg-RX-API-DMAC7.html)
CN (1) CN106687107B (cg-RX-API-DMAC7.html)
AU (1) AU2015301596B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017002761A2 (cg-RX-API-DMAC7.html)
CA (1) CA2955666A1 (cg-RX-API-DMAC7.html)
IL (1) IL250568B (cg-RX-API-DMAC7.html)
MX (1) MX2017001971A (cg-RX-API-DMAC7.html)
RU (1) RU2697851C2 (cg-RX-API-DMAC7.html)
WO (1) WO2016025762A1 (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9289418B2 (en) 2013-03-15 2016-03-22 Cedars-Sinai Medical Center Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens
CA2903493C (en) 2013-03-15 2022-05-31 Cedars-Sinai Medical Center Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens
US9956292B2 (en) 2014-08-13 2018-05-01 Cedars-Sinai Medical Center Anti-methanogenic compositions and uses thereof
US10736871B2 (en) 2015-04-01 2020-08-11 Cedars-Sinai Medical Center Anti-methanogenic lovastatin analogs or derivatives and uses thereof
EP3302442B1 (en) 2015-06-03 2024-10-16 Triastek, Inc. Dosage forms and use thereof
US10219518B2 (en) * 2015-09-18 2019-03-05 Environmental Intellectual Property, Inc. Inhibition of methanogenesis to control wood boring insects and pestilence
WO2017200876A1 (en) * 2016-05-19 2017-11-23 Synthetic Biologics, Inc. Anti-methanogenic compositions
WO2017223177A1 (en) * 2016-06-21 2017-12-28 Cedars-Sinai Medical Center Clinically efficacious anti-methanogenic compositions and uses
WO2018112215A1 (en) * 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
EP4190318A1 (en) 2016-12-14 2023-06-07 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a jak inhibitor and devices
CN118873822A (zh) * 2016-12-14 2024-11-01 比奥拉治疗股份有限公司 使用tnf抑制剂治疗胃肠道疾病
WO2018137686A1 (en) * 2017-01-26 2018-08-02 Triastek, Inc. Dosage forms of controlled release at specific gastrointestinal sites
US11464744B2 (en) 2017-06-21 2022-10-11 Minerva Neurosciences, Inc. Gastro-resistant controlled release oral dosage forms
BR112021004523A2 (pt) * 2018-09-10 2021-06-08 Argenta Innovation Limited formulações para liberação sustentada em dispositivos de administração
WO2021072092A1 (en) * 2019-10-09 2021-04-15 R.P. Scherer Technologies, Llc Non-animal softgel capsule formulations, methods of preparation, and methods of use thereof
EP4477215A3 (en) 2020-12-08 2025-02-19 Ruminant Biotech Corp Limited Improvements to devices and methods for delivery of substances to animals
US20240389885A1 (en) * 2021-10-19 2024-11-28 Cedars-Sinai Medical Center Daily fasting methane to detect intestinal methanogen overgrowth and monitor treatment response
WO2023119207A1 (en) * 2021-12-23 2023-06-29 Fonterra Co-Operative Group Limited Use of lactic acid bacteria to improve feed efficiency
US12084610B2 (en) 2022-07-01 2024-09-10 Arkea Bio Corp. Compositions and methods for reducing deleterious atmospheric gas emissions from flooded ecosystems
WO2025036806A1 (en) * 2023-08-15 2025-02-20 Evonik Operations Gmbh An enteric coated hard shell capsule for delivery of a dosage form in the ileum and colon
US12448600B2 (en) 2023-08-24 2025-10-21 Synergraze Inc. Extraction of antimethanogenic compounds
US12281342B2 (en) 2023-08-24 2025-04-22 Synergraze Inc. Extraction of antimethanogenic compounds

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US225202A (en) * 1880-03-02 Clothes-slide
GB423083A (en) 1934-05-22 1935-01-24 Hugh Edwin Johnstone Peake Improvements in and relating to the manufacture of fermented beverages and medicinalpreparations
JPS60133852A (ja) 1983-12-23 1985-07-17 Zenkoku Shokubutsu Tanpaku Shokuhin Kyodo Kumiai 新規な納豆製品
DE3718638A1 (de) 1987-06-04 1988-12-22 Thomae Gmbh Dr K Neue phenylethanolamine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
JPH03275630A (ja) 1990-03-23 1991-12-06 Hayashikane Sangyo Kk 肝機能改善剤及び肝機能改善食品又は飲料
US5225202A (en) * 1991-09-30 1993-07-06 E. R. Squibb & Sons, Inc. Enteric coated pharmaceutical compositions
EP0724454B1 (en) 1993-10-19 2004-03-24 Commonwealth Scientific And Industrial Research Organisation Method for improving utilisation of nutrients by ruminant or ruminant-like animals
US5447850A (en) 1994-01-31 1995-09-05 Mccann; James L. Method of producing methane from organic waste
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US6562629B1 (en) 1999-08-11 2003-05-13 Cedars-Sinai Medical Center Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum
US6558708B1 (en) 1995-05-17 2003-05-06 Cedars-Sinai Medical Center Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
KR19990014865A (ko) 1995-05-17 1999-02-25 피터 이. 브래이브맨 소장에서의 소화 및 흡수를 증진시키기 위한, 지방산을 함유한조성물들
JP3010007B2 (ja) 1995-05-22 2000-02-14 ビオフェルミン製薬株式会社 配合下剤
US5840332A (en) 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
US5889038A (en) 1996-03-20 1999-03-30 Children's Hospital Methods and products for treating diarrhea and scours: use of clotrimazole and related aromatic compounds
GB9711962D0 (en) 1997-06-10 1997-08-06 Reckitt & Colmann Prod Ltd Therapeutically active compositions
CN1119154C (zh) 1998-01-20 2003-08-27 上海信谊药业有限公司 双歧三联活菌制剂及制备方法
US6368591B2 (en) 1998-05-15 2002-04-09 Shanghai Sine Pharmaceutical Corporation Ltd. Beneficial microbe composition, new protective materials for the microbes, method to prepare the same and uses thereof
US5985907A (en) 1998-08-12 1999-11-16 Health Research, Inc. Method for inhibiting growth of methanogens
US6328959B1 (en) 1998-09-18 2001-12-11 The United States Of America As Represented By The Secretary Of The Navy Intestinal hydrogen removal using hydrogen-metabolizing microbes
AU2161000A (en) * 1998-12-07 2000-06-26 Bristol-Myers Squibb Company Enteric coated pravastatin bead formulation
EP1242064A4 (en) 1999-11-03 2005-02-09 Smith Howard J & Ass Pty Ltd LIFE-SPECIFIC THERAPY
WO2001034123A1 (en) 1999-11-08 2001-05-17 Andrx Corporation Hmg-coa reductase inhibitor extended release formulation
AU2001269015B2 (en) 2000-06-13 2004-10-14 Unilever Plc Non-viable lactobacillus containing food product
US6299774B1 (en) 2000-06-26 2001-10-09 Jack L. Ainsworth Anaerobic digester system
AU2002344820B2 (en) * 2001-06-20 2006-12-14 Merck & Co., Inc. Dipeptidyl peptidase inhibitors for the treatment of diabetes
WO2003100023A2 (en) 2002-05-20 2003-12-04 Cedars-Sinai Medical Center Manipulation of the rate of gastrointestinal transit by modulating intestinal methane concentration
US10066254B2 (en) 2002-05-20 2018-09-04 Cedars-Sinai Medical Center Diagnosis of constipation by analysis of methane concentration
IL166339A0 (en) 2002-07-18 2006-01-16 Kemire Phosphates Pty Ltd Megasphaera elsdenii strain and its uses
JP2006503023A (ja) 2002-09-03 2006-01-26 バイオヴェイル ラボラトリーズ インコーポレイテッド スタチン薬物の放出調節ための医薬品製剤および方法
PL375712A1 (en) * 2002-09-03 2005-12-12 Biovail Laboratories Inc. Pravastatin pharmaceutical formulations and methods of their use
ITBO20020564A1 (it) 2002-09-06 2004-03-07 Alfa Wassermann Spa Bifidobatteri e preparazioni che li contengono.
CA2541753A1 (en) 2003-07-10 2005-01-20 Michelle Alfa Combination therapy for gastroenteric diseases caused by microorganisms
MY147202A (en) * 2003-11-26 2012-11-14 Novartis Ag Compositions comprising organic compounds
AU2003289546A1 (en) 2003-12-16 2005-07-05 Uk Chemipharm Co., Ltd. Process for preparing simvastatin.
US8007827B2 (en) * 2004-04-02 2011-08-30 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties
AU2005247195A1 (en) 2004-05-27 2005-12-08 Dexcel Pharma Technologies Ltd Localized controlled absorption of statins in the gastrointestinal tract for achieving high blood levels of statins
US20060111436A1 (en) 2004-11-23 2006-05-25 John Griffin Compositions and treatments for modulating kinase and/or HMG-CoA reductase
US20100048595A1 (en) 2005-03-23 2010-02-25 Washington University In St. Louis Use of archaea to modulate the nutrient harvesting functions of the gastrointestinal microbiota
WO2006102536A2 (en) 2005-03-23 2006-09-28 University Of Southern California Treatment of disease conditions through modulation of hydrogen sulfide produced by small intestinal bacterial overgrowth
EP2079448A2 (en) * 2006-10-10 2009-07-22 Dexcel Pharma Technologies Ltd. Improved release of statins in the intestine
EP2102350A4 (en) 2006-12-18 2012-08-08 Univ St Louis DARMMICROBIOMA AS A BIOMARKER AND THERAPEUTIC OBJECT FOR THE TREATMENT OF ADIPOSITAS OR ADIPOSITASCONDUCTIVE DISEASES
WO2008151032A2 (en) 2007-05-31 2008-12-11 Washington University In St. Louis Arrays and methods comprising m. smithii gene products
ES2559319T3 (es) * 2007-06-04 2016-02-11 Synergy Pharmaceuticals Inc. Agonistas de guanilato cliclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
US7970905B2 (en) 2008-07-03 2011-06-28 International Business Machines Corporation Method, system and computer program product for server selection, application placement and consolidation planning of information technology systems
WO2010088633A2 (en) 2009-02-02 2010-08-05 Chromocell Corporation Novel cell lines and methods
UY32802A (es) 2009-07-23 2011-01-31 Provimi Holding B V Composiciones para reducir la metanogénesis gastrointestinal en rumiantes
US20130230498A1 (en) 2010-02-16 2013-09-05 Arizona Board Of Regents For And On Behalf Of Arizona State University Reducing short-chain fatty acids and energy uptake in obese humans by managing their intestinal microbial communities
KR101298788B1 (ko) * 2011-03-15 2013-08-22 보령제약 주식회사 안정성이 개선된 복합제제
CN103230593A (zh) * 2012-10-30 2013-08-07 辽宁亿灵科创生物医药科技有限公司 一种治疗胃肠疾病的药物组合物
EP2943213A4 (en) * 2013-01-08 2016-08-17 Jerome Schentag ACTIVATION OF THE ENDOGENOUS HORMONE PATHWAY OF ILLEAL BRAKE FOR THE REGENERATION OF AN ORGAN AND ASSOCIATED COMPOSITIONS, METHODS OF TREATMENT, DIAGNOSTICS, AND REGULATORY SYSTEMS
CN103142552A (zh) * 2013-02-22 2013-06-12 广州科的信医药技术有限公司 一种洛伐他汀肠溶缓释微丸胶囊及其制备方法
CA2903493C (en) 2013-03-15 2022-05-31 Cedars-Sinai Medical Center Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens
US9289418B2 (en) 2013-03-15 2016-03-22 Cedars-Sinai Medical Center Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens
US9956292B2 (en) 2014-08-13 2018-05-01 Cedars-Sinai Medical Center Anti-methanogenic compositions and uses thereof
US10736871B2 (en) 2015-04-01 2020-08-11 Cedars-Sinai Medical Center Anti-methanogenic lovastatin analogs or derivatives and uses thereof
WO2017223177A1 (en) 2016-06-21 2017-12-28 Cedars-Sinai Medical Center Clinically efficacious anti-methanogenic compositions and uses

Also Published As

Publication number Publication date
RU2697851C2 (ru) 2019-08-21
JP2017528516A (ja) 2017-09-28
KR20170041769A (ko) 2017-04-17
JP6667526B2 (ja) 2020-03-18
EP3179983A1 (en) 2017-06-21
US10668159B2 (en) 2020-06-02
KR102425303B1 (ko) 2022-07-25
US20160045604A1 (en) 2016-02-18
EP3179983A4 (en) 2018-01-10
US20180289816A1 (en) 2018-10-11
CN106687107A (zh) 2017-05-17
RU2017106896A (ru) 2018-09-13
US20200323781A1 (en) 2020-10-15
AU2015301596B2 (en) 2020-04-16
WO2016025762A1 (en) 2016-02-18
IL250568B (en) 2021-05-31
US9956292B2 (en) 2018-05-01
CA2955666A1 (en) 2016-02-18
IL250568A0 (en) 2017-03-30
AU2015301596A1 (en) 2017-02-02
US20190328885A1 (en) 2019-10-31
US20230036151A1 (en) 2023-02-02
CN106687107B (zh) 2020-12-25
BR112017002761A2 (pt) 2017-12-19
MX2017001971A (es) 2017-09-15
US11344501B2 (en) 2022-05-31
US10328151B2 (en) 2019-06-25

Similar Documents

Publication Publication Date Title
BR112016018076A2 (cg-RX-API-DMAC7.html)
BR112016016195A2 (cg-RX-API-DMAC7.html)
BR112016015813A2 (cg-RX-API-DMAC7.html)
BR112016016951A2 (cg-RX-API-DMAC7.html)
BR112016018238A2 (cg-RX-API-DMAC7.html)
BR112016017303A2 (cg-RX-API-DMAC7.html)
BR112016016088A2 (cg-RX-API-DMAC7.html)
BR112016015605A2 (cg-RX-API-DMAC7.html)
BR112016016094A2 (cg-RX-API-DMAC7.html)
BR112016016741A2 (cg-RX-API-DMAC7.html)
BR112016018369A2 (cg-RX-API-DMAC7.html)
RU2017106896A3 (cg-RX-API-DMAC7.html)
BR112016017657A2 (cg-RX-API-DMAC7.html)
BR112016016451A2 (cg-RX-API-DMAC7.html)
BR112016017137A2 (cg-RX-API-DMAC7.html)
BR112016016751A2 (cg-RX-API-DMAC7.html)
BR112016018575A2 (cg-RX-API-DMAC7.html)
BR112016018705A2 (cg-RX-API-DMAC7.html)
BR112016015779A2 (cg-RX-API-DMAC7.html)
BR112016016992A2 (cg-RX-API-DMAC7.html)
BR112016016268A2 (cg-RX-API-DMAC7.html)
BR112016016944A2 (cg-RX-API-DMAC7.html)
BR112016015768A2 (cg-RX-API-DMAC7.html)
BR112016017216A2 (cg-RX-API-DMAC7.html)
BR112016014482A2 (cg-RX-API-DMAC7.html)

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20200814

NF4A Reinstatement of patent

Effective date: 20210823